Belgium· BE-AMP-SAM543937-00
Trecondi 1 g
A treosulfan product containing treosulfan, registered in Belgium by Medac. The same ATC class is registered in 16 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Treosulfan is registered in 16 of 19 countries.
Countries holding a registration under ATC L01AB02 (treosulfan), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Treosulfan · ATC L01AB02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Treosulfan
- Manufacturer
- Medac
- Country
- Belgium (BE)
- ATC code
- L01AB02
- ATC class
- Treosulfan
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4951661
- be_apb7743941
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Treosulfan in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRECONDIMedac Gesellschaft für klinische Spezialpräparate m.b.H., Wedel
- FinlandTrecondiMedac Gesellschaft Für Klinische Spezialpräparate mbH
- IrelandTrecondi 1 g powder for solution for infusionmedac Gesellschaft für klinische Spezialpräparate mbH
- IcelandTrecondimedac Gesellschaft für klinische Spezialpräparate GmbH
- NorwayTrecondiMedac - Gesellschaft für klinische Spezialpräparate Gmbh - Wedel
- PolandTrecondimedac Gesellschaft fuer klinische Spezialpraeparate mbH
- SwedenTrecondi 1 g Pulver till infusionsvätska, lösningmedac Gesellschaft für klinische Spezialpräparate mbH
- United KingdomTrecondi 1g powder for solution for infusionmedac UK
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Treosulfan Tillomed
- Czechia · Treosulfan Tillomed
- Germany · Ovastat, Treosulfan Tillomed
- Denmark · Treosulfan Tillomed
- Spain · Treosulfano Zentiva
- Finland · Treosulfan Tillomed
- France · Treosulfan Tillomed
- United Kingdom (Northern Ireland) · Treosulfan Tillomed Laboratories
- Greece · Treosulfan Tillomed
- Ireland · Treosulfan Tillomed
- Iceland · Trecondi
- Liechtenstein · Trecondi
- Netherlands · Treosulfan Tillomed
- Norway · Trecondi, Treosulfan Tillomed
- Poland · Treosulfan Zentiva
- Portugal · Treossulfano Tillomed
- Romania · Treosulfan Tillomed
- Sweden · Treosulfan Tillomed
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7394c57f-5841-4b74-867e-a4dc21b97d05 GET /v1/drugs/7394c57f-5841-4b74-867e-a4dc21b97d05?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Trecondi 1 g",
"name_fr": "Trecondi 1 g",
"name_nl": "Trecondi 1 g",
"amp_code": "SAM543937-00",
"strengths": [
"1.0000"
],
"pack_count": 2,
"substances": [
"Treosulfan"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Treosulfan",
"authorisation_numbers": [
"EU/1/18/1351/001",
"EU/1/18/1351/002"
]
}See everything about treosulfan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.